Sino-Argi Leading Biosciences
Sino-Agri Leading Biosciences Co.,Ltd engages in pesticide distribution in China and internationally. The company sells technical materials, formulations, and related products. It also provides plant protection technology services; and crop health solutions, including technical guidance, application demonstration, and processing and packaging of plant protection products. In addition, the company… Read more
Sino-Argi Leading Biosciences (603970) - Total Liabilities
Latest total liabilities as of September 2025: CN¥4.85 Billion CNY
Based on the latest financial reports, Sino-Argi Leading Biosciences (603970) has total liabilities worth CN¥4.85 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sino-Argi Leading Biosciences - Total Liabilities Trend (2012–2024)
This chart illustrates how Sino-Argi Leading Biosciences's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sino-Argi Leading Biosciences Competitors by Total Liabilities
The table below lists competitors of Sino-Argi Leading Biosciences ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MEDIPOST Co. Ltd
KQ:078160
|
Korea | ₩109.40 Billion |
|
Hunan Zhenghong Science and Technology Develop Co Ltd
SHE:000702
|
China | CN¥212.28 Million |
|
Evans Bancorp Inc
NYSE MKT:EVBN
|
USA | $2.00 Billion |
|
D&L Industries Inc
PINK:DALQF
|
USA | $30.12 Billion |
|
Vista Group International Ltd
AU:VGL
|
Australia | AU$91.22 Million |
|
Fujian Fynex Textile Science & Technology Co Ltd
SHG:600493
|
China | CN¥657.74 Million |
|
FDC Limited
NSE:FDC
|
India | ₹4.54 Billion |
|
United Arrows Ltd.
PINK:UTDAY
|
USA | $34.36 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Sino-Argi Leading Biosciences's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sino-Argi Leading Biosciences's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sino-Argi Leading Biosciences (2012–2024)
The table below shows the annual total liabilities of Sino-Argi Leading Biosciences from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥3.92 Billion | -11.20% |
| 2023-12-31 | CN¥4.41 Billion | -7.26% |
| 2022-12-31 | CN¥4.76 Billion | +37.53% |
| 2021-12-31 | CN¥3.46 Billion | +20.14% |
| 2020-12-31 | CN¥2.88 Billion | +69.95% |
| 2019-12-31 | CN¥1.69 Billion | +4.13% |
| 2018-12-31 | CN¥1.63 Billion | -15.07% |
| 2017-12-31 | CN¥1.92 Billion | -10.86% |
| 2016-12-31 | CN¥2.15 Billion | -0.99% |
| 2015-12-31 | CN¥2.17 Billion | +30.13% |
| 2014-12-31 | CN¥1.67 Billion | +19.92% |
| 2013-12-31 | CN¥1.39 Billion | +40.36% |
| 2012-12-31 | CN¥991.46 Million | -- |